SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

-	-							
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) (First) (Middle) 270 UNIVERSITY AVENUE 3. Date of Earliest Transaction (Month/Day/Year) below) (Street) 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicab Line) PALO ALTO CA 94301 X Form filed by One Reporting Person Form filed by More than One Reporting Person	1. Name and Address of Reporting Person [*] Bogue Zachary	2. Issuer Name and Ticker or Trading Symbol <u>RECURSION PHARMACEUTICALS</u> , <u>INC.</u> [RXRX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (circe title
(Street) PALO ALTO CA 94301 Form filed by More than One Reporting Person			Officer (give title Other (specify below) below)
	PALO ALTO CA 94301	4. If Amendment, Date of Original Filed (Month/Day/Year)	X Form filed by One Reporting Person Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Ownership
			Code	v	Amount (A) or Price 1		Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Class A Common Stock	10/01/2021		A		295 ⁽¹⁾	A	\$0.00	781	D	
Class A Common Stock								5,941,120	Ι	See footnote ⁽²⁾
Class A Common Stock								3,951,141	Ι	See footnote ⁽³⁾
Class A Common Stock								3,726,963	Ι	See footnote ⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

2. Represents shares held of record by Data Collective IV, L.P. ("DCVC IV"). Data Collective IV GP, LLC ("DCVC IV GP") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial owner ship of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any.

3. Represents shares held of record by DCVC Opportunity Fund II, L.P. ("DCVC Opp Fund II"). DCVC Opportunity Fund II GP, LLC ("DCVC Opp Fund II GP") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power withrespect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any.

4. Represents shares held of record by DCVC V, L.P. ("DCVC V"). DCVC V GP, LLC ("DCVC V GP") is the general partner of DCVC V and has sole voting and dispositive power with regard to the shares held by DCVC V. Matthew Ocko and Zachary Bogue are the managing members of DCVC V GP and share voting and dispositive power with respect to the shares held by DCVC V. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any.

Remarks:

<u>/s/ Nathan Hatfield, attorney-</u> <u>10/05/2021</u> <u>in-fact</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.